News
Press Releases
NEW YORK and PETACH TIKVAH, Israel, Nov. 5, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the third quarter financial results. Dial-in and replay information are provided below.
|
Conference Call & Webcast |
|
|
Thursday, November 13, 2014 at 8:30 a.m. EST/5:30 a.m. PST |
|
|
Domestic: |
888-438-5525 |
|
International: |
719-457-2083 |
|
Conference ID: |
5950362 |
|
Webcast: |
|
|
|
|
|
Replays – Available through November 27, 2014 |
|
|
Domestic: |
877-870-5176 |
|
International: |
858-384-5517 |
|
Conference ID: |
5950362 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
SOURCE BrainStorm Cell Therapeutics Inc.